Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Fibrolamellar hepatocellular carcinoma × durvalumab × 30 days × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 23 Lung Neoplasms 17 Small Cell Lung Carcinoma 9 Urinary Bladder Neoplasms 6 Neoplasms 6 Carcinoma, Hepatocellular 6 Cholangiocarcinoma 5 Biliary Tract Neoplasms 5 Liver Neoplasms 4 Neoplasms by Site 3 Triple Negative Breast Neoplasms 2 Thoracic Neoplasms 2 Stomach Neoplasms 2 Respiratory Tract Neoplasms 2 Respiratory Tract Diseases 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Lung Diseases 2 Gallbladder Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Bronchogenic 2 Carcinoma 2 Bronchial Neoplasms 2 Breast Neoplasms 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1

Interventions

poly ICLC 1 pembrolizumab 1 atezolizumab 1 Specimen Handling 1 Sorafenib 1 Nivolumab 1 Irinotecan 1 Ipilimumab 1 DT2216 1 Cyclophosphamide 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡